Barinthus Biotherapeutics (BRNS) Revenue (2020 - 2024)

Barinthus Biotherapeutics (BRNS) has reported Revenue for 5 consecutive years, with $15.0 million the latest figure, recorded in Q3 2024.

• For the quarter ending Q3 2024, Revenue changed N/A year-over-year to $15.0 million; the trailing twelve-month figure through Dec 2025 stood at $15.0 million (changed 0.0% YoY), and the FY2024 full-year result was $15.0 million, up 1766.46% from the prior year.
• Revenue advanced to $15.0 million in Q3 2024 per BRNS's latest filing, from $334000.0 in the prior quarter.
• Across five years, Revenue topped out at $17.1 million in Q2 2022 and bottomed at -$1000.0 in Q4 2021.
• Historically, Revenue has averaged $4.4 million across 5 years, with a median of $511000.0 in 2020.
• The sharpest annual moves came in 2021 and 2022: Revenue tumbled 100.28% in 2021, then surged 645800.0% in 2022.
• Over 5 years, Revenue stood at $354000.0 in 2020, then sank by 100.28% to -$1000.0 in 2021, then soared by 645800.0% to $6.5 million in 2022, then tumbled by 94.83% to $334000.0 in 2023, then surged by 4381.74% to $15.0 million in 2024.
• According to Business Quant data, Revenue over the past three periods registered $15.0 million, $334000.0, and $468000.0 for Q3 2024, Q2 2023, and Q1 2023 respectively.